EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase III)Randomisierte kontrollierte StudieVergleichsstudieOpen Access · CC BY-NC-ND 4.0

Non‐Inferiority of Subcutaneous Efepoetin Alfa Compared to Methoxy Polyethylene Glycol‐Epoetin Beta in Stage 3 or 4 CKD Patients: Insights From a Phase 3 Trial

Simon D Roger iD, Chew Ming Wong, Phisitt Vejakama, Kuspudji Dwitanto Rahardjo, Bang-Gee Hsu, Chang Meng Lee, I-Wen Wu iD, Chin-Chan Lee, Tunggul Diapari Situmorang, Pajaree Krisanapan, Sadanah Aqashiah Mazlan, Yu-Sen Peng und 34 weitere

Nephrology · 2025

DOI: 10.1111/nep.70046 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Nephrology, 2025. Verfasst von Simon D Roger und 45 weiteren Autor:innen. Beteiligte Einrichtung: Renal Research, Gosford, New South Wales, Australia. Hauptthemen laut MEDLINE: Polyethylene Glycols, Renal Insufficiency, Chronic, Anemia, Hematinics. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Kalbe Genexine Biologics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Efepoetin alfa, a novel long‐acting erythropoietin (EPO)‐hybrid Fc fusion protein, represents a promising erythropoiesis‐stimulating agent (ESA) for addressing anaemia in chronic kidney disease (CKD) patients. This Phase 3 trial was to assess the efficacy and tolerability of subcutaneous efepoetin alfa in comparison to subcutaneous methoxy polyethylene glycol‐epoetin beta in stage 3 or 4 CKD patients.

Methods

A randomised, multicentre, open‐label Phase 3 trial enrolled 391 CKD stage 3 or stage 4 patients. Subjects underwent a 20‐week correction period followed by an 8‐week evaluation period. Responders continued treatment for an extra 24‐week extension to evaluate long‐term safety, maintenance effectiveness, and the longer treatment interval.

Results

In the efepoetin alfa Q2W (every 2 weeks) group, the response rate was 75.6%; while in the methoxy polyethylene glycol‐epoetin beta Q2W group, the response rate was 69.3%. The difference in the response rate was 6.3% with 95% CI (confidence interval) –3.1% to 15.5%. The lower limit of the 95% CI was above the prespecified non‐inferiority margin of −9.0%. Adverse event rates were comparable between the treatment groups.

Conclusion

Efepoetin alfa demonstrated non‐inferiority to methoxy polyethylene glycol‐epoetin beta in correcting anaemia and maintaining haemoglobin (Hb) levels among stage 3 and 4 CKD patients. Moreover, the safety profile of efepoetin alfa was comparable to methoxy polyethylene glycol‐epoetin beta.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polyethylene GlycolsRenal Insufficiency, ChronicAnemiaHematinicsErythropoietinRecombinant Fusion ProteinsHumansMaleFemaleMiddle AgedAgedInjections, SubcutaneousTreatment OutcomeHemoglobinsTime FactorsAdultBiomarkersRecombinant Proteins

Stichwörter der Autor:innen

anaemiachronic kidney diseaseefepoetin alfalong‐acting erythropoiesis‐stimulating agent

Substanzen

Polyethylene GlycolsHematinicsErythropoietinmonomethoxypolyethylene glycolHemoglobinsRecombinant Fusion Proteinsepoetin betaBiomarkersRecombinant Proteins

Autor:innen und Institutionen

  • Renal Research, Gosford, New South Wales, Australia.
  • University Malaya Medical Centre, Petaling Jaya, Malaysia.
  • Sunpasitthiprasong Hospital, Ubon Ratchathani, Thailand.
  • Islam Cempaka Putih Hospital, Jakarta, Indonesia.
  • Islam Pondok Kopi Hospital, Jakarta, Indonesia.
  • Hualien Tzu Chi Hospital, Hualien City, Taiwan.

ORCID-Profile: Simon D Roger, I-Wen Wu, Rey Isidto, Kajohnsak Noppakun, Mohamad Zaimi Abdul Wahab, Seok Joon Shin

Förderung

  • Kalbe Genexine Biologics

Zitieren

APA

Roger, S. D., Wong, C. M., Vejakama, P., Rahardjo, K. D., Hsu, B. G., Lee, C. M., Wu, I. W., Lee, C. C., Situmorang, T. D., Krisanapan, P., Mazlan, S. A., Peng, Y. S., Sarwono, J., De Asis, N., Solimen, D., Jonny, Sangthawan, P., Chen, J. B., Wang, C. L., …, & Nugroho, P. (2025). Non‐Inferiority of Subcutaneous Efepoetin Alfa Compared to Methoxy Polyethylene Glycol‐Epoetin Beta in Stage 3 or 4 CKD Patients: Insights From a Phase 3 Trial. Nephrology. https://doi.org/10.1111/nep.70046

Vancouver

Roger SD, Wong CM, Vejakama P, Rahardjo KD, Hsu BG, Lee CM, et al. Non‐Inferiority of Subcutaneous Efepoetin Alfa Compared to Methoxy Polyethylene Glycol‐Epoetin Beta in Stage 3 or 4 CKD Patients: Insights From a Phase 3 Trial. Nephrology. 2025. doi:10.1111/nep.70046

BibTeX
@article{Roger2025,
  author = {Roger, Simon D and Wong, Chew Ming and Vejakama, Phisitt and Rahardjo, Kuspudji Dwitanto and Hsu, Bang-Gee and Lee, Chang Meng and Wu, I-Wen and Lee, Chin-Chan and Situmorang, Tunggul Diapari and Krisanapan, Pajaree and Mazlan, Sadanah Aqashiah and Peng, Yu-Sen and Sarwono, Johanes and De Asis, Norman and Solimen, Domingo and Jonny and Sangthawan, Pornpen and Chen, Jin-Bor and Wang, Chia-Liang and Chung, Sungjin and Villaflor, Agnes Jeans and Yang, Chul Woo and Kan, Wei-Chih and Yang, Yu and Rubio-Bicol, Jenny and Yan, Lee Yee and Lee, Sang Ho and Chiu, Yi-Wen and Chen, Cheng-Hsu and Na, Ki Young and Hassah, Wan Hasnul Halimi Wan and Kang, Young Sun and Choi, Bum-Soon and Aquitania, Grace and Na, Ki Ryang and Wu, Mai-Szu and Ahmad, Mohd Kamil and Isidto, Rey and Wu, Vincent and Leong, Goh Bak and Sung, Junne-Ming and Noppakun, Kajohnsak and Chou, Kang-Ju and Abdul Wahab, Mohamad Zaimi and Shin, Seok Joon and Nugroho, Pringgodigdo},
  title = {Non‐Inferiority of Subcutaneous Efepoetin Alfa Compared to Methoxy Polyethylene Glycol‐Epoetin Beta in Stage 3 or 4 CKD Patients: Insights From a Phase 3 Trial},
  journal = {Nephrology},
  year = {2025},
  doi = {10.1111/nep.70046}
}
Kostenlos starten →